HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Clinical trials for HIGH-RISK SMOLDERING MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK SMOLDERING MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for HIGH-RISK SMOLDERING MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Matched conditions: HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 19:21 UTC
-
Four-Drug cocktail aims to halt smoldering myeloma before it strikes
Disease control OngoingThis phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…
Matched conditions: HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated Jul 03, 2026 19:21 UTC
-
Promising combo aims to stop smoldering myeloma in its tracks
Disease control OngoingThis phase 3 trial tests whether adding isatuximab (Sarclisa) to standard lenalidomide and dexamethasone can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combo or the two-drug s…
Matched conditions: HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC